Skip to main content
Springer Nature Link
Log in

βIII-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Aims

βIII-tubulin (TUBB3) is a microtubule component overexpression of which is found in many solid cancer types, often linked to poor patient prognosis, and has been suggested to predict failure of microtubule-targeting chemotherapeutics. This study was designed to determine prevalence and prognostic impact of TUBB3 expression in kidney cancers.

Methods and results

A tissue microarray (TMA) containing more than 1,200 renal tumors was analyzed by immunohistochemistry. TUBB3 expression varied markedly between the different histological subtypes and was more frequent in 105 papillary cancers (75.2 %, p < 0.0001), 38 oncocytomas (52.6 %, p < 0.0001), and 22 chromophobic carcinomas (36.4 %, p = 0.1221) than in 555 clear cell RCC (16.4 %). In clear cell cancers, strong TUBB3 positivity was linked to high Fuhrman grade (p < 0.0001), advanced stage (0.002), nodal metastases (p = 0.0433), hematogenous metastases (p = 0.0016), and shortened overall survival (p < 0.0001). Associations with outcome and tumor phenotype were inversely for papillary RCC, where TUBB3 immunostaining was linked to low tumor stage (p = 0.0012) and prolonged survival (p = 0.0043).

Conclusions

TUBB3 expression levels and their effects are strikingly different between ccRCC and papillary RCC. These differences may be caused by differences in VHL function between these RCC subtypes, because VHL (like TUBB3) is another strong regulator of microtubule function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277–300. doi:10.3322/caac.20073

    Article  PubMed  Google Scholar 

  2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6):1374–1403. doi:10.1016/j.ejca.2012.12.027

    Article  CAS  PubMed  Google Scholar 

  3. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB (2003) Mechanisms of taxol resistance related to microtubules. Oncogene 22(47):7280–7295. doi:10.1038/sj.onc.1206934

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Katsetos CD, Legido A, Perentes E, Mork SJ (2003) Class III beta-tubulin isotype: a key cytoskeletal protein at the crossroads of developmental neurobiology and tumor neuropathology. J Child Neurol 18(12):851–866 (discussion 867)

    Article  PubMed  Google Scholar 

  5. Leandro-Garcia LJ, Leskela S, Landa I, Montero-Conde C, Lopez-Jimenez E, Leton R, Cascon A, Robledo M, Rodriguez-Antona C (2010) Tumoral and tissue-specific expression of the major human beta-tubulin isotypes. Cytoskeleton 67(4):214–223. doi:10.1002/cm.20436

    Article  CAS  PubMed  Google Scholar 

  6. Ferrandina G, Legge F, Salutari V, Paglia A, Testa A, Scambia G (2006) Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations. Eur J Cancer 42(14):2296–2302. doi:10.1016/j.ejca.2006.03.025

    Article  PubMed  Google Scholar 

  7. Hetland TE, Hellesylt E, Florenes VA, Trope C, Davidson B, Kaern J (2011) Class III beta-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance. Hum Pathol 42(7):1019–1026. doi:10.1016/j.humpath.2010.10.025

    Article  CAS  PubMed  Google Scholar 

  8. Koh Y, Jang B, Han SW, Kim TM, Oh DY, Lee SH, Kang CH, Kim DW, Im SA, Chung DH, Kim YT, Kim TY, Kim YW, Kim JH, Heo DS, Bang YJ (2010) Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J thorac oncol 5(3):320–325. doi:10.1097/JTO.0b013e3181ce684f

    Article  PubMed  Google Scholar 

  9. Zhang HL, Ruan L, Zheng LM, Whyte D, Tzeng CM, Zhou XW (2012) Association between class III beta-tubulin expression and response to paclitaxel/vinorelbine-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung Cancer 77(1):9–15. doi:10.1016/j.lungcan.2012.01.005

    Article  PubMed  Google Scholar 

  10. Zhou J, Li J, Wang Z, Yin C, Zhang W (2012) Metadherin is a novel prognostic marker for bladder cancer progression and overall patient survival. Asia Pac j clin oncol 8(3):e42–e48. doi:10.1111/j.1743-7563.2012.01541.x

    Article  PubMed  Google Scholar 

  11. Zheng WE, Chen H, Yuan SF, Wu LL, Zhang W, Sun HY, Chen WJ (2012) Overexpression of betaIII-tubulin and survivin associated with drug resistance to docetaxel-based chemotherapy in advanced gastric cancer. J BUON 17(2):284–290

    PubMed  Google Scholar 

  12. Zhang P, Ma X, Song E, Chen W, Pang H, Ni D, Gao Y, Fan Y, Ding Q, Zhang Y, Zhang X (2013) Tubulin cofactor a functions as a novel positive regulator of ccRCC progression, invasion and metastasis. Int j cancer. doi:10.1002/ijc.28306

    Google Scholar 

  13. Ferguson RE, Taylor C, Stanley A, Butler E, Joyce A, Harnden P, Patel PM, Selby PJ, Banks RE (2005) Resistance to the tubulin-binding agents in renal cell carcinoma: no mutations in the class I beta-tubulin gene but changes in tubulin isotype protein expression. Clin cancer res 11(9):3439–3445. doi:10.1158/1078-0432.CCR-04-2049

    Article  CAS  PubMed  Google Scholar 

  14. Minner S, Rump D, Tennstedt P, Simon R, Burandt E, Terracciano L, Moch H, Wilczak W, Bokemeyer C, Fisch M, Sauter G, Eichelberg C (2012) Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. Cancer 118(5):1268–1275. doi:10.1002/cncr.26436

    Article  CAS  PubMed  Google Scholar 

  15. Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6(7):655–663

    Article  CAS  PubMed  Google Scholar 

  16. Ploussard G, Terry S, Maille P, Allory Y, Sirab N, Kheuang L, Soyeux P, Nicolaiew N, Coppolani E, Paule B, Salomon L, Culine S, Buttyan R, Vacherot F, de la Taille A (2010) Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res 70(22):9253–9264. doi:10.1158/0008-5472.CAN-10-1447

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS, Simon R, Tennstedt P, Muller J, Scholz L, Brase JC, Liu AY, Schluter H, Pantel K, Schumacher U, Bokemeyer C, Steuber T, Graefen M, Sauter G, Schlomm T (2011) ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 17(18):5878–5888. doi:10.1158/1078-0432.CCR-11-1251

    Article  CAS  PubMed  Google Scholar 

  18. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP, Sauter G (2001) Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159(6):2249–2256

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Ruiz C, Seibt S, Al Kuraya K, Siraj AK, Mirlacher M, Schraml P, Maurer R, Spichtin H, Torhorst J, Popovska S, Simon R, Sauter G (2006) Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int j cancer 118(9):2190–2194

    Article  CAS  PubMed  Google Scholar 

  20. Nocito A, Bubendorf L, Tinner EM, Suess K, Wagner U, Forster T, Kononen J, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knonagel H, Rist M, Anabitarte M, Hering F, Hardmeier T, Schoenenberger AJ, Flury R, Jager P, Fehr JL, Schraml P, Moch H, Mihatsch MJ, Gasser T, Sauter G (2001) Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 194(3):349–357. doi:10.1002/1096-9896(200107)194:3<349:AID-PATH887>3.0.CO;2-D

    Article  CAS  PubMed  Google Scholar 

  21. Moch H, Schraml P, Bubendorf L, Mirlacher M, Kononen J, Gasser T, Mihatsch MJ, Kallioniemi OP, Sauter G (1999) High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol 154(4):981–986

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Simon R, Mirlacher M, Sauter G (2005) Tissue microarrays. Methods Mol Med 114:257–268. doi:10.1385/1-59259-923-0:257

    CAS  PubMed  Google Scholar 

  23. Steurer S, Seddiqi AS, Singer JM, Bahar AS, Eichelberg C, Rink M, Dahlem R, Huland H, Sauter G, Simon R, Minner S, Burandt E, Stahl PR, Schlomm T, Wurlitzer M, Schluter H (2014) MALDI imaging on tissue microarrays identifies molecular features associated with renal cell cancer phenotype. Anticancer Res 34(5):2255–2261

    PubMed  Google Scholar 

  24. Tsourlakis MC, Weigand P, Grupp K, Kluth M, Steurer S, Schlomm T, Graefen M, Huland H, Salomon G, Steuber T, Wilczak W, Sirma H, Simon R, Sauter G, Minner S, Quaas A (2013) betaIII-Tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion. Am J Pathol. doi:10.1016/j.ajpath.2013.11.007

    PubMed  Google Scholar 

  25. Horak CE, Pusztai L, Xing G, Trifan OC, Saura C, Tseng LM, Chan S, Welcher R, Liu D (2013) Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer. Clin cancer res 19(6):1587–1595. doi:10.1158/1078-0432.CCR-12-1359

    Article  CAS  PubMed  Google Scholar 

  26. Levallet G, Bergot E, Antoine M, Creveuil C, Santos AO, Beau-Faller M, de Fraipont F, Brambilla E, Levallet J, Morin F, Westeel V, Wislez M, Quoix E, Debieuvre D, Dubois F, Rouquette I, Pujol JL, Moro-Sibilot D, Camonis J, Zalcman G (2012) High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway. Mol Cancer Ther 11(5):1203–1213. doi:10.1158/1535-7163.MCT-11-0899

    Article  CAS  PubMed  Google Scholar 

  27. Katsetos CD, Herman MM, Mork SJ (2003) Class III beta-tubulin in human development and cancer. Cell Motil Cytoskeleton 55(2):77–96. doi:10.1002/cm.10116

    Article  CAS  PubMed  Google Scholar 

  28. Gao S, Zhao X, Lin B, Hu Z, Yan L, Gao J (2012) Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance. Tumour biol 33(5):1759–1765. doi:10.1007/s13277-012-0435-y

    Article  CAS  PubMed  Google Scholar 

  29. Carrara L, Guzzo F, Roque DM, Bellone S, Emiliano C, Sartori E, Pecorelli S, Schwartz PE, Rutherford TJ, Santin AD (2012) Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression. Gynecol Oncol 125(1):231–236. doi:10.1016/j.ygyno.2011.12.446

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Panda D, Miller HP, Banerjee A, Luduena RF, Wilson L (1994) Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci USA 91(24):11358–11362

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Falconer MM, Echeverri CJ, Brown DL (1992) Differential sorting of beta tubulin isotypes into colchicine-stable microtubules during neuronal and muscle differentiation of embryonal carcinoma cells. Cell Motil Cytoskeleton 21(4):313–325. doi:10.1002/cm.970210407

    Article  CAS  PubMed  Google Scholar 

  32. Schoumacher M, Goldman RD, Louvard D, Vignjevic DM (2010) Actin, microtubules, and vimentin intermediate filaments cooperate for elongation of invadopodia. J cell biol 189(3):541–556. doi:10.1083/jcb.200909113

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Schnaeker EM, Ossig R, Ludwig T, Dreier R, Oberleithner H, Wilhelmi M, Schneider SW (2004) Microtubule-dependent matrix metalloproteinase-2/matrix metalloproteinase-9 exocytosis: prerequisite in human melanoma cell invasion. Cancer Res 64(24):8924–8931. doi:10.1158/0008-5472.CAN-04-0324

    Article  CAS  PubMed  Google Scholar 

  34. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies H, Edkins S, Hardy C, Latimer C, Teague J, Andrews J, Barthorpe S, Beare D, Buck G, Campbell PJ, Forbes S, Jia M, Jones D, Knott H, Kok CY, Lau KW, Leroy C, Lin ML, McBride DJ, Maddison M, Maguire S, McLay K, Menzies A, Mironenko T, Mulderrig L, Mudie L, O’Meara S, Pleasance E, Rajasingham A, Shepherd R, Smith R, Stebbings L, Stephens P, Tang G, Tarpey PS, Turrell K, Dykema KJ, Khoo SK, Petillo D, Wondergem B, Anema J, Kahnoski RJ, Teh BT, Stratton MR, Futreal PA (2010) Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463(7279):360–363. doi:10.1038/nature08672

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Dulaimi E, Ibanez de Caceres I, Uzzo RG, Al-Saleem T, Greenberg RE, Polascik TJ, Babb JS, Grizzle WE, Cairns P (2004) Promoter hypermethylation profile of kidney cancer. Clin cancer res 10(12 Pt 1):3972–3979. doi:10.1158/1078-0432.CCR-04-0175

    Article  CAS  PubMed  Google Scholar 

  36. Thoma CR, Matov A, Gutbrodt KL, Hoerner CR, Smole Z, Krek W, Danuser G (2010) Quantitative image analysis identifies pVHL as a key regulator of microtubule dynamic instability. J cell biol 190(6):991–1003. doi:10.1083/jcb.201006059

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Lolkema MP, Mehra N, Jorna AS, van Beest M, Giles RH, Voest EE (2004) The von Hippel-Lindau tumor suppressor protein influences microtubule dynamics at the cell periphery. Exp Cell Res 301(2):139–146. doi:10.1016/j.yexcr.2004.07.016

    Article  CAS  PubMed  Google Scholar 

  38. Jordan MA, Toso RJ, Thrower D, Wilson L (1993) Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90(20):9552–9556

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  39. Dumontet C, Sikic BI (1999) Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 17(3):1061–1070

    CAS  Google Scholar 

  40. Seve P, Dumontet C (2008) Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 9(2):168–175. doi:10.1016/S1470-2045(08)70029-9

    Article  CAS  PubMed  Google Scholar 

  41. Narvi E, Jaakkola K, Winsel S, Oetken-Lindholm C, Halonen P, Kallio L, Kallio MJ (2013) Altered TUBB3 expression contributes to the epothilone response of mitotic cells. Br J Cancer 108(1):82–90. doi:10.1038/bjc.2012.553

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  42. Lu Q, Luduena RF (1993) Removal of beta III isotype enhances taxol induced microtubule assembly. Cell Struct Funct 18(3):173–182

    Article  CAS  PubMed  Google Scholar 

  43. Banerjee A, Roach MC, Trcka P, Luduena RF (1990) Increased microtubule assembly in bovine brain tubulin lacking the type III isotype of beta-tubulin. J Biol Chem 265(3):1794–1799

    CAS  PubMed  Google Scholar 

  44. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, Poruchynsky MS (1997) Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272(27):17118–17125

    Article  CAS  PubMed  Google Scholar 

  45. Tommasi S, Mangia A, Lacalamita R, Bellizzi A, Fedele V, Chiriatti A, Thomssen C, Kendzierski N, Latorre A, Lorusso V, Schittulli F, Zito F, Kavallaris M, Paradiso A (2007) Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins. Int J cancer 120(10):2078–2085. doi:10.1002/ijc.22557

    Article  CAS  PubMed  Google Scholar 

  46. Seve P, Mackey J, Isaac S, Tredan O, Souquet PJ, Perol M, Lai R, Voloch A, Dumontet C (2005) Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4(12):2001–2007. doi:10.1158/1535-7163.MCT-05-0244

    Article  CAS  PubMed  Google Scholar 

  47. Mertens WC, Eisenhauer EA, Jolivet J, Ernst S, Moore M, Muldal A (1994) Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Ann oncol 5(2):185–187

    CAS  PubMed  Google Scholar 

  48. Bruntsch U, Heinrich B, Kaye SB, de Mulder PH, van Oosterom A, Paridaens R, Vermorken JB, Wanders J, Franklin H, Bayssas M et al (1994) Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group. Eur J Cancer 30A(8):1064–1067

    Article  CAS  PubMed  Google Scholar 

  49. Bylow KA, Atkins MB, Posadas EM, Stadler WM, McDermott DF (2009) Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma. Clin genitourin cancer 7(1):39–42. doi:10.3816/CGC.2009.n.007

    Article  CAS  PubMed  Google Scholar 

  50. Walpole ET, Dutcher JP, Sparano J, Gucalp R, Einzig A, Paietta E, Ciobanu N, Grima K, Caliendo G, Cavasotto G et al (1993) Survival after phase II treatment of advanced renal cell carcinoma with taxol or high-dose interleukin-2. J immunotherapy emphasis tumor immunol 13(4):275–281

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We thank Christina Koop, Janett Lütgens, Sünje Seekamp, and Inge Brandt for excellent technical support.

Conflict of interest

There are no proprietary interests, and no financial support was received. No conflicts of interest regarding the article exist.

Author information

Authors and Affiliations

  1. Department of Pathology, Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany

    Alexander Quaas, Amir-Hossein Rahvar, Christoph Burdelski, Christina Koop, Maria Christina Tsourlakis, Ronald Simon, Sarah Minner, Guido Sauter & Stefan Steurer

  2. Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    Christian Eichelberg, Michael Rink & Roland Dahlem

  3. Martini Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    Thorsten Schlomm

Authors
  1. Alexander Quaas
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Amir-Hossein Rahvar
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Christoph Burdelski
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Christina Koop
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Christian Eichelberg
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Michael Rink
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Roland Dahlem
    View author publications

    You can also search for this author inPubMed Google Scholar

  8. Thorsten Schlomm
    View author publications

    You can also search for this author inPubMed Google Scholar

  9. Maria Christina Tsourlakis
    View author publications

    You can also search for this author inPubMed Google Scholar

  10. Ronald Simon
    View author publications

    You can also search for this author inPubMed Google Scholar

  11. Sarah Minner
    View author publications

    You can also search for this author inPubMed Google Scholar

  12. Guido Sauter
    View author publications

    You can also search for this author inPubMed Google Scholar

  13. Stefan Steurer
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Stefan Steurer.

Additional information

Alexander Quaas and Amir-Hossein Rahvar have contributed equally to this work.

Electronic supplementary material

Below is the link to the electronic supplementary material.

345_2014_1463_MOESM1_ESM.jpg

Prognostic impact of different levels of TUBB3 immunostaining on overall survival of patients with clear cell (ccRCC) and papillary (papRCC) renal cell cancers (JPEG 357 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Quaas, A., Rahvar, AH., Burdelski, C. et al. βIII-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma. World J Urol 33, 1561–1569 (2015). https://doi.org/10.1007/s00345-014-1463-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-014-1463-6

Keywords